Skip to main content
AAN.com
Editorial
March 29, 2017

Viral hepatitis and the risk of Parkinson disease

April 25, 2017 issue
88 (17) 1596-1597

Abstract

Parkinson disease (PD) is a chronic progressive neurodegenerative disorder with a relatively high incidence.1 PD seems to result from a complicated interplay of genetic and environmental factors affecting numerous fundamental cellular processes.2 However, the ultimate cause of loss of dopaminergic neurons in the substantia nigra pars compacta remains to be determined.2 An outright definitive cure for the disease remains elusive, leaving both patients and their caregivers with the challenge of living with a chronic medical condition that affects their health-related quality of life.2 It is therefore imperative to focus research efforts on the search for the etiology of this condition.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Benito-León J, Bermejo-Pareja F, Morales-González JM, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004;62:734–741.
2.
Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912.
3.
Ghadery C, Koshimori Y, Coakeley S, et al. Microglial activation in Parkinson's disease using [18F]-FEPPA. J Neuroinflammation 2017;14:8.
4.
Arai H, Furuya T, Mizuno Y, Mochizuki H. Inflammation and infection in Parkinson's disease. Histol Histopathol 2006;21:673–678.
5.
Bu XL, Wang X, Xiang Y, et al. The association between infectious burden and Parkinson's disease: a case-control study. Parkinsonism Relat Disord 2015;21:877–881.
6.
Wu WY, Kang KH, Chen SL, et al. Hepatitis C virus infection: a risk factor for Parkinson's disease. J Viral Hepat 2015;22:784–791.
7.
Tsai HH, Liou HH, Muo CH, Lee CZ, Yen RF, Kao CH. Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study. Neurology 2016;86:840–846.
8.
Pakpoor J, Noyce A, Goldacre R, et al. Viral hepatitis and Parkinson disease: a national record-linkage study. Neurology 2017;88:1630–1633.
9.
Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002;76:600–608.
10.
He Q, He Q, Qin X, et al. The relationship between inflammatory marker levels and hepatitis C virus severity. Gastroenterol Res Pract 2016;2016:2978479.

Information & Authors

Information

Published In

Neurology®
Volume 88Number 17April 25, 2017
Pages: 1596-1597
PubMed: 28356459

Publication History

Published online: March 29, 2017
Published in print: April 25, 2017

Permissions

Request permissions for this article.

Disclosure

The author reports no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Study Funding

Dr. Benito-León is supported by the NIH (NINDS #R01 NS39422), the Commission of the European Union (grant ICT-2011-287739, NeuroTREMOR), the Ministry of Economy and Competitiveness (grant RTC-2015-3967-1, NetMD-platform for the tracking of movement disorder), and the Spanish Health Research Agency (grants FIS PI12/01602 and FIS PI16/00451).

Authors

Affiliations & Disclosures

Julián Benito-León, MD, PhD
From the Department of Neurology, University Hospital “12 de Octubre”; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED); and Department of Medicine, Complutense University, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. Benito-León: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the editorial.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview, Frontiers in Oncology, 12, (2022).https://doi.org/10.3389/fonc.2022.913231
    Crossref
  2. Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease, Frontiers in Aging Neuroscience, 12, (2020).https://doi.org/10.3389/fnagi.2020.00012
    Crossref
  3. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism, Movement Disorders, 34, 12, (1882-1890), (2019).https://doi.org/10.1002/mds.27848
    Crossref
  4. Is Interferon Therapy for Hepatitis C Infection a Treatable Risk Factor for Parkinson Disease?, JAMA Neurology, 76, 9, (1006), (2019).https://doi.org/10.1001/jamaneurol.2019.1377
    Crossref
  5. T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis, Journal of Medical Genetics, 56, 1, (22-28), (2018).https://doi.org/10.1136/jmedgenet-2018-105570
    Crossref
  6. Evidence for association between hepatitis C virus and Parkinson’s disease, Neurological Sciences, 38, 11, (1913-1920), (2017).https://doi.org/10.1007/s10072-017-3077-4
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share